Phase II clinical trial of pazopanib with unresectable or metastatic malignant peripheral nerve sheath tumor (1st cohort) and in patients with chemoresistant tumors; alveolar soft part sarcoma, epithelioid sarcoma, and clear cell sarcoma (2nd cohort)

Phase II clinical trial of pazopanib with unresectable or metastatic malignant peripheral nerve sheath tumor (1st cohort) and in patients with chemoresistant tumors; alveolar soft part sarcoma, epithelioid sarcoma, and clear cell sarcoma (2nd cohort) - Phase II clinical trial of pazopanib in patients with malignant peripheral nerve sheath tumor or chemoresistant tumor

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019303

Enrollment

Registered

2015-10-09

Start date

2016-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1st cohort: patients with unresectable or metastatic malignant peripheral nerve sheath tumor, 2nd cohort: patients with chemoresistant tumors

Interventions

pazopanib 800mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1st cohort: patients with unresectable or metastatic malignant peripheral nerve sheath tumor, 2nd cohort: patients with unresectable or metastatic chemoresistant tumors; alveolar soft part sarcoma, epithelioid sarcoma, and clear cell sarcoma

Exclusion criteria

Exclusion criteria: cerebrovascular disease, gastrointestinal disorder, bleeding tendency, hypersensitivity, pregnancy

Design outcomes

Primary

Measure	Time frame
clinical benefit rate at 12 weeks (RECIST)	—

Secondary

Measure	Time frame
clinical benefit rate at 12 weeks (Choi), response rate and progression free survival (RECIST/Choi), overall survival, safety	—

Countries

Japan

Contacts

Public ContactHiroshi Urakawa

Nagoya University Graduate School and School of Medicine Department of Orthopaedic Surgery

urakawa@med.nagoya-u.ac.jp052-744-1908

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026